CSL Ltd (CSL)

Currency in AUD
114.87
-2.78(-2.36%)
Closed·
Advertisement
CSL is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
114.39117.15
52 wk Range
90.00275.79
Key Statistics
Bid/Ask
114.87 / 115.00
Prev. Close
117.65
Open
114.6
Day's Range
114.39-117.15
52 wk Range
90-275.79
Volume
2.31M
Average Volume (3m)
1.91M
1-Year Change
-52.1335%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CSL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
139.99
Upside
+21.87%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

CSL Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

7 Buy
9 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 139.99
(+21.87% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Hold107.00-6.85%113.00Maintain16/06/2026
UBS
Buy158.00+37.55%175.00Maintain10/06/2026
Jefferies
Hold108.00-5.98%195.00Downgrade28/05/2026
Citi
Hold110.00-4.24%200.00Downgrade13/05/2026
CLSA
Buy145.00+26.23%200.00Maintain12/05/2026

CSL Ltd Earnings Call Summary for H1/2026

  • CSL Limited reported an 81% drop in net profit after tax for H1 2026 due to one-off costs, with revenue falling 4% to $8.3 billion and stock price declining 11.77% to $162.03.
  • Despite financial challenges, the company maintained its interim dividend at $1.30 per share and reaffirmed its full-year guidance, expecting double-digit IG growth in H2.
  • Interim CEO Gordon Naylor announced a transformation program targeting $550 million in annual cost savings by FY2028, while projecting high single-digit NPAT growth for FY2027-FY2028.
  • Management anticipates recovery in albumin sales in China and continues to focus on margin expansion, while acknowledging challenges in KCENTRA, perioperative bleeding segments, and Medicare Part D impacts.
Last Updated: 11/02/2026, 00:38
Read Full Transcript

Earnings

Latest Release
18/08/2025
EPS / Forecast
2.04 / 2.70
Revenue / Forecast
7.08B / 10.2B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.86%
Dividend Yield
3.62%
Industry Median 2.44%
Annualised payout
4.26
Paid unevenly
5-Years Growth
+6.71%
Growth Streak

CSL (CSL) Income Statement & Profits

Compare CSL to Peers and Sector

Metrics to compare
CSL
Peers
Sector
Relationship
P/E Ratio
27.2x22.0x−0.4x
PEG Ratio
−0.55−1.790.00
Price/Book
2.0x2.4x2.6x
Price / LTM Sales
2.5x2.7x3.0x
Upside (Analyst Target)
15.5%40.1%56.9%
Fair Value Upside
Unlock10.0%9.3%Unlock

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Employees
29904
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
110.71M23.12%12.72B
Other Institutional Investors
77.76M16.24%8.93B
Public Companies & Retail Investors
290.44M60.65%33.36B
Total
478.91M100.00%55.01B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
State Street Global Advisors, Inc.8.24%39,466,3834,533,503
BlackRock, Inc.6.98%33,446,6303,842,014

People Also Watch

118.03
COH
+1.27%
51.79
ASX
-0.19%
249.360
MQG
-0.25%
63.14
MIN
-1.56%
40.240
WOW
+0.75%

FAQ

What Is the CSL (Sydney: CSL) Share Price Today?

The CSL stock price today is 114.87 AUD.

What Stock Exchange Does CSL (CSL) Trade On?

CSL is listed and trades on the Sydney Stock Exchange.

What Is the Ticker (Stock Symbol) for CSL?

The stock symbol (also called a 'ticker') for CSL is "CSL."

Does CSL Pay Dividends? What’s The Current CSL Dividend Yield?

Yes, CSL Pays Dividends to its Shareholders. The current CSL dividend yield is 3.62%.

What Is the Current CSL Market Capitalisation?

As of today, CSL (Sydney: CSL) market cap is 55.01B AUD.

What Is CSL's (CSL) Earnings Per Share (TTM)?

The CSL EPS is currently 2.86 (Trailing Twelve Months).

Is CSL a Buy or Sell From a Technical Analyst Perspective?

Based on today's CSL moving averages and other technical indicators, the daily buy/sell signal for CSL stock is Strong Buy.

How Many Times Has CSL Stock Split?

CSL has split 1 times. (See the CSL stock split history page for full effective split date and price information.)

How Many Employees Does CSL Have?

CSL has 29904 employees, based on their latest Companies House report.

What is the current trading status of CSL (Sydney: CSL)?

As of 27/06/2026, CSL (CSL) is trading at a share price of 114.87 AUD, with a previous close of 117.65 AUD. The stock has fluctuated within a day range of 114.39 AUD to 117.15 AUD, while its 52-week range spans from 90.00 AUD to 275.79 AUD.

What Is CSL (CSL) Price Target According to Analysts?

The average 12-month price target for CSL is 139.99 AUD, with a high estimate of 201.06827076 AUD and a low estimate of 104.95868967 AUD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21.87% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.